NEW FOR 2017 - Late-Breaking Clinical Trials and First Report Investigations
We are excited to announce that we will be accepting abstract submissions for the newly added Late-Breaking Clinical Trials And First Report Investigations Session at the 22nd Annual International Atrial Fibrillation Symposium on January 12-14, 2017 in Orlando, Florida. Accepted Late-Breaking Clinical Trials And First Report Investigations will be presented in a dedicated session featuring not-yet-published clinical research findings in the field of atrial fibrillation. Accepted abstracts will be published in JCE.
It is with great pleasure that I invite you to attend the 22nd Annual International AF Symposium on January 12-14, 2017 at the Hyatt Regency in Orlando, Florida. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 22 years, the meeting has become a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field.
This intensive, highly focused three-day symposium brings together the world’s leading medical scientists to share in a highly interactive environment the most recent advances in the field of atrial fibrillation. The primary objective of the meeting is to provide attendees with a thorough and practical course on the current state of the art in the field of atrial fibrillation in a scholarly and collegial atmosphere, as well as an opportunity to network with colleagues and faculty between sessions. The meeting employs advanced teaching tools including real-time and prerecorded case presentations as well as an interactive audience response system to share with attendees the most current basic, translational and clinical science in the field.
The past two decades have witnessed dramatic advances in all areas of AF research. These developments have contributed to major progress in our understanding of the pathophysiology of this arrhythmia and to the development of safer and more effective strategies for the management of AF and the prevention of AF-related stroke. The AF Symposium is dedicated to bringing these advances to our attendees each year in an exceptionally organized and exciting scientific program.
After 18 years in Boston, the meeting was moved to Orlando, Florida, in 2014, where we were pleased to offer our attendees, faculty and industry partners the opportunity to be housed in one facility. The Hyatt Regency Orlando, our location for 2017, is located just 15 minutes from Orlando International Airport. In 2017, the AF Symposium again looks forward to offering attendees and exhibitors easy and comfortable access to the symposium, housing, and a wide range of amenities, all within a single convention facility. In keeping with the rapid advances in the field, the 2017 AF Symposium promises to be an exciting and enlightening meeting. We hope that you will join us.
Jeremy Ruskin, MD